Literature DB >> 10027824

Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: A statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association.

H Gutgesell, D Atkins, R Barst, M Buck, W Franklin, R Humes, R Ringel, R Shaddy, K A Taubert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10027824     DOI： 10.1161/01.cir.99.7.979

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  15 in total

Review 1.  Understanding attention-deficit/hyperactivity disorder from childhood to adulthood.

Authors:  Timothy E Wilens; Thomas J Spencer
Journal:  Postgrad Med       Date:  2010-09       Impact factor: 3.840

Review 2.  An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults.

Authors:  Timothy E Wilens; Nicholas R Morrison; Jefferson Prince
Journal:  Expert Rev Neurother       Date:  2011-10       Impact factor: 4.618

Review 3.  The QT interval and psychotropic medications in children: recommendations for clinicians.

Authors:  Paul McNally; Fiona McNicholas; Paul Oslizlok
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-08-29       Impact factor: 4.785

4.  Functional abdominal pain and irritable bowel syndrome in children and adolescents.

Authors:  Eric Chiou; Samuel Nurko
Journal:  Therapy       Date:  2011-05-01

Review 5.  Management of functional abdominal pain and irritable bowel syndrome in children and adolescents.

Authors:  Eric Chiou; Samuel Nurko
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2010-06       Impact factor: 3.869

Review 6.  Clinical utility of aVR-The neglected electrocardiographic lead.

Authors:  Dmitriy Kireyev; Mikhail V Arkhipov; Stephen T Zador; Joseph A Paris; William E Boden
Journal:  Ann Noninvasive Electrocardiol       Date:  2010-04       Impact factor: 1.468

Review 7.  Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?

Authors:  Jochen Antel; Özgür Albayrak; Gerd Heusch; Tobias Banaschewski; Johannes Hebebrand
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-08-23       Impact factor: 5.270

Review 8.  Pharmacological management of attention-deficit hyperactivity disorder in adolescents: special considerations.

Authors:  Philip Hazell
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 9.  Attention-deficit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reason.

Authors:  Anjan S Batra; Mark E Alexander; Michael J Silka
Journal:  Pediatr Cardiol       Date:  2012-03       Impact factor: 1.655

10.  An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness.

Authors:  Timothy E Wilens; Paul Hammerness; Linsey Utzinger; Mary Schillinger; Anna Georgiopoulous; Robert L Doyle; Marykate Martelon; Kerry Brodziak
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-10       Impact factor: 2.576
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.